Investment Management Associates Inc. ADV Sells 7,035 Shares of McKesson Corporation $MCK

Investment Management Associates Inc. ADV decreased its holdings in McKesson Corporation (NYSE:MCK) by 38.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 11,045 shares of the company’s stock after selling 7,035 shares during the quarter. McKesson accounts for 2.5% of Investment Management Associates Inc. ADV’s investment portfolio, making the stock its 16th biggest holding. Investment Management Associates Inc. ADV’s holdings in McKesson were worth $9,060,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Swedbank AB boosted its position in shares of McKesson by 42.2% during the fourth quarter. Swedbank AB now owns 886,283 shares of the company’s stock valued at $727,009,000 after buying an additional 263,189 shares during the last quarter. SurgoCap Partners LP boosted its position in shares of McKesson by 68.7% during the third quarter. SurgoCap Partners LP now owns 452,261 shares of the company’s stock valued at $349,390,000 after buying an additional 184,106 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its position in shares of McKesson by 73.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 432,578 shares of the company’s stock valued at $354,839,000 after buying an additional 183,590 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in shares of McKesson during the third quarter valued at approximately $135,352,000. Finally, Danske Bank A S purchased a new position in shares of McKesson during the third quarter valued at approximately $127,487,000. Institutional investors own 85.07% of the company’s stock.

McKesson Price Performance

Shares of NYSE MCK opened at $734.93 on Friday. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00. The business’s fifty day moving average price is $883.74 and its 200-day moving average price is $859.93. The stock has a market capitalization of $90.02 billion, a PE ratio of 19.10, a P/E/G ratio of 1.09 and a beta of 0.35.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, beating analysts’ consensus estimates of $11.56 by $0.13. McKesson had a negative return on equity of 378.75% and a net margin of 1.18%.The firm had revenue of $96.30 billion for the quarter, compared to analysts’ expectations of $101.35 billion. During the same quarter in the prior year, the firm earned $10.12 EPS. The business’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, equities analysts expect that McKesson Corporation will post 44.24 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s dividend payout ratio is currently 8.53%.

Insider Activity

In other news, EVP Michele Lau sold 2,725 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the transaction, the executive vice president owned 3,247 shares of the company’s stock, valued at $3,214,530. This represents a 45.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Maria Martinez sold 349 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the transaction, the director directly owned 301 shares in the company, valued at $282,900.87. This represents a 53.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,264 shares of company stock valued at $3,205,315 in the last 90 days. Insiders own 0.08% of the company’s stock.

Analyst Upgrades and Downgrades

MCK has been the topic of several analyst reports. Wall Street Zen raised McKesson from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings reaffirmed a “buy (b+)” rating on shares of McKesson in a research report on Monday. Barclays lifted their target price on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Raymond James Financial set a $970.00 target price on McKesson in a research report on Thursday, March 5th. Finally, JPMorgan Chase & Co. cut their target price on McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating on the stock in a research report on Friday. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $970.73.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat quarterly adjusted EPS estimates, reporting $11.69 per share versus $11.56 expected, and cited strength in oncology, specialty distribution, and biopharma services. Reuters article
• Positive Sentiment: The company guided fiscal 2027 EPS to $43.80-$44.60, which is roughly in line with expectations and suggests continued earnings growth. McKesson also reaffirmed its long-term financial targets. Yahoo Finance article
• Positive Sentiment: JPMorgan lowered its price target to $1,015 from $1,107 but kept an overweight rating, implying meaningful upside from the current share price. Benzinga article
• Positive Sentiment: William Blair reiterated a Buy rating, saying McKesson’s durable earnings power and fiscal 2027 growth outlook outweigh near-term revenue softness. TipRanks article
• Neutral Sentiment: McKesson advanced plans for its $13 billion medical-surgical spinoff/separation, a strategic move that could unlock value over time but also adds execution risk. MSN article
• Negative Sentiment: Revenue came in below Wall Street forecasts at $96.3 billion versus $101.35 billion expected, reinforcing concerns about softer sales momentum despite improved margins. Yahoo Finance article
• Negative Sentiment: The stock has been trading lower as investors focus on the revenue shortfall and near-term softness in the medical-surgical business, even with strong earnings and guidance. Zacks article

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.